Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.

Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
E Merck: Impressive results from the vitamin king - Views on News from Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks


Login Failure
(Please do not use this option on a public machine)
  Sign Up | Forgot Password?  

E Merck: Impressive results from the vitamin king

Jul 21, 2000

E Merck has reported an impressive growth of 79% in net profits at Rs 113.61 million for the quarter ended June 30, 2000 over the same period in the last fiscal. This, despite the fact that the sales have grown by 9.85% only. A part of the reason for this growth is that the company had written off VRS expenditure paid to the workers when it closed its Taloja plant. Besides, E Merck repaid a part of its borrowings last year, which has also contributed to the surge in the bottomline.

(Rs m) 1QFY00 1QFY01 Change
Sales 721 791 9.8%
Other Income 17 9 -48.9%
Expenditure 625 628 0.6%
Operating Profit (EBDIT) 96 163 70.0%
Operating Profit Margin (%) 13.3% 20.6%  
Interest (net) 9 (1)  
Depreciation 17 15 -12.9%
Profit before Tax 87 158 81.5%
Other Adjustments      
Tax 23 44 87.7%
Profit after Tax/(Loss) 63 114 79.2%
Net profit margin (%) 8.8% 14.4%  
No. of Shares (m) (eoy) 16.8 16.8  
Diluted no. of shares (m) 16.8 16.8  
Diluted Earnings per share* 15.1 27.0  

The company produces vitamins Evion, Neurobion and Polybion which are leaders in their respective categories. These contribute almost 45% of the company's turnover. All the three are under price control and are likely to remain that way for some time to come.

However, the company’s new launches, i.e. Candistat capsules, a modern antibacterial, and Harpoon tablets, a quinoline antibiotic, are doing very well. Evion cream launched last year is also doing well. Thus the non-vitamin segments have been showing improvement in the turnover while the vitamin segment reamins a major contributory factor to the turnover.

In the non-pharma divisions, all the business units have done well in the turnover as well as profitability. The new product range has been included in the Reagents and Diagnostics range. Manufacturing and marketing of vitamin/mineral premixes for food industry, addition of products for filtration, electronic balances, water purification systems, testing equipment for food and gas industry and substantial expansion of product range of laboratory reagents are some of the new introductions in the non-pharma division.

The stock quotes at a price of Rs 365, which implies an earning multiple of 18.7 times its annualised earnings for the year ending December 2000.

Equitymaster requests your view! Post a comment on "E Merck: Impressive results from the vitamin king". Click here!


More Views on News

MERCK Announces Quarterly Results (4QFY19); Net Profit Up 79.2% (Quarterly Result Update)

May 13, 2019 | Updated on May 13, 2019

For the quarter ended March 2019, MERCK has posted a net profit of Rs 407 m (up 79.2% YoY). Sales on the other hand came in at Rs 2 bn (down 23.3% YoY). Read on for a complete analysis of MERCK's quarterly results.

MERCK LTD Announces Quarterly Results (3QFY19); Net Profit Up 31.3% (Quarterly Result Update)

Mar 5, 2019 | Updated on Mar 5, 2019

For the quarter ended December 2018, MERCK LTD has posted a net profit of Rs 135 m (up 31.3% YoY). Sales on the other hand came in at Rs 2 bn (down 32.8% YoY). Read on for a complete analysis of MERCK LTD's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Shalby Ltd. (IPO)

Dec 2, 2017

Should you subscribe to the IPO of Shalby Ltd?

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

My Top 7 Stocks to Profit from Sensex 100,000(The 5 Minute Wrapup)

May 16, 2019

Tanushree Banerjee explains everything you need to know about the Rebirth of India and Sensex 100,000.

3 Stocks to Bet on to Become a 'Dividend Millionaire'(Profit Hunter)

May 14, 2019

As markets continue to rattle amid earning season, upcoming elections, volatile crude price and US China trade war, it's a great idea to add some stability to your portfolio by adding dividend stocks.

Indian Steel: The Perfect Multibagger Opportunity(Profit Hunter)

May 17, 2019

A structurally strong Indian Steel Industry will help India achieve 8%+ GDP growth in the coming years.

My Top 7 Stocks to Buy as Modi Returns to Power(The 5 Minute Wrapup)

May 23, 2019

The Modi government is all set to come back to power. With a stable government at the centre, how should you play the stock market?

What Makes TVS Srichakra and CCL Products a Cut Above the Rest?(The 5 Minute Wrapup)

May 17, 2019

Despite the commodity nature of their businesses, these two stocks have rewarded shareholders well.


Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms


May 24, 2019 (Close)